AU2014227737B2 - Meropenem derivatives and uses thereof - Google Patents

Meropenem derivatives and uses thereof Download PDF

Info

Publication number
AU2014227737B2
AU2014227737B2 AU2014227737A AU2014227737A AU2014227737B2 AU 2014227737 B2 AU2014227737 B2 AU 2014227737B2 AU 2014227737 A AU2014227737 A AU 2014227737A AU 2014227737 A AU2014227737 A AU 2014227737A AU 2014227737 B2 AU2014227737 B2 AU 2014227737B2
Authority
AU
Australia
Prior art keywords
alkyl
certain embodiments
substituted
kda
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014227737A
Other languages
English (en)
Other versions
AU2014227737A1 (en
Inventor
James BOURASSA
Hongming Chen
Yen CU
Elizabeth M. Enlow
Jinsoo Kim
Pawel Wojciech Nowak
Winston Zapanta ONG
Alexey Popov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kala Bio Inc
Original Assignee
Kala Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kala Bio Inc filed Critical Kala Bio Inc
Publication of AU2014227737A1 publication Critical patent/AU2014227737A1/en
Priority to AU2018203005A priority Critical patent/AU2018203005A1/en
Application granted granted Critical
Publication of AU2014227737B2 publication Critical patent/AU2014227737B2/en
Assigned to KALA BIO, Inc. reassignment KALA BIO, Inc. Request to Amend Deed and Register Assignors: KALA PHARMACEUTICALS, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014227737A 2013-03-15 2014-03-14 Meropenem derivatives and uses thereof Ceased AU2014227737B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018203005A AU2018203005A1 (en) 2013-03-15 2018-05-01 Meropenem derivatives and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361789335P 2013-03-15 2013-03-15
US61/789,335 2013-03-15
PCT/US2014/028627 WO2014144285A1 (en) 2013-03-15 2014-03-14 Meropenem derivatives and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018203005A Division AU2018203005A1 (en) 2013-03-15 2018-05-01 Meropenem derivatives and uses thereof

Publications (2)

Publication Number Publication Date
AU2014227737A1 AU2014227737A1 (en) 2015-10-08
AU2014227737B2 true AU2014227737B2 (en) 2018-05-17

Family

ID=51537664

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014227737A Ceased AU2014227737B2 (en) 2013-03-15 2014-03-14 Meropenem derivatives and uses thereof
AU2018203005A Abandoned AU2018203005A1 (en) 2013-03-15 2018-05-01 Meropenem derivatives and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018203005A Abandoned AU2018203005A1 (en) 2013-03-15 2018-05-01 Meropenem derivatives and uses thereof

Country Status (8)

Country Link
US (4) US9725451B2 (cg-RX-API-DMAC10.html)
EP (1) EP2968274B1 (cg-RX-API-DMAC10.html)
JP (2) JP2016517435A (cg-RX-API-DMAC10.html)
AU (2) AU2014227737B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015023621A8 (cg-RX-API-DMAC10.html)
CA (1) CA2906689A1 (cg-RX-API-DMAC10.html)
HK (1) HK1219233A1 (cg-RX-API-DMAC10.html)
WO (1) WO2014144285A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111362239B (zh) * 2020-03-20 2021-07-06 辽宁瑞鸥新材料科技有限公司 一种用于铝硅系合金半固态制浆的Cs2HPO4气溶胶及其使用方法
CN112076161B (zh) * 2020-08-07 2022-10-18 安徽康正康仁药业有限公司 一种头孢菌素类钠盐与丙磺舒钠组成的复方冻干制剂
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
CA3216616A1 (en) * 2021-04-27 2022-11-03 Philip V. Felice Compositions comprising cocrystals of acetylsalicylic acid and theanine with tromethamine and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015078A1 (en) * 1992-02-04 1993-08-05 Zeneca Limited Carbapenems containing a carboxy substituted phenyl group, processes for their preparation, intermediates and use as antibiotics
US20040176350A1 (en) * 2001-05-21 2004-09-09 Hiroshi Matsui Carbapenem compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA84584B (en) * 1983-01-28 1984-09-26 Bristol Myers Co Substituted vinyl cephalosporins
DE3475065D1 (en) * 1983-06-23 1988-12-15 Merck & Co Inc (acyloxyalkoxy) carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs, their preparation and pharmaceutical compositions containing said derivatives
US4914091A (en) * 1984-04-02 1990-04-03 American Cyanamid Company Esters of cephalosporin derivitives
JPS6247874A (ja) 1985-08-27 1987-03-02 Sankyo Seiki Mfg Co Ltd プログラム動作装置の初期化方法
JPH06192273A (ja) * 1992-10-26 1994-07-12 Lederle Japan Ltd カルバペネム−３−カルボン酸エステル誘導体
AU3649697A (en) * 1996-06-27 1998-01-14 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
JP2000344773A (ja) * 1998-07-17 2000-12-12 Kyoto Pharmaceutical Industries Ltd カルバペネム誘導体、およびその用途並びにその中間体化合物
JP2000344772A (ja) 1998-05-01 2000-12-12 Kyoto Pharmaceutical Industries Ltd カルバペネム誘導体、その用途およびその中間体化合物
SK16382000A3 (sk) 1998-05-01 2001-05-10 Kyoto Pharmaceutical Industries, Ltd. Karbapénové deriváty, ich vyžitie a ich medziproduktové zlúčeniny
JP2000344774A (ja) * 1999-06-03 2000-12-12 Meiji Seika Kaisha Ltd カルバペネム類の製造法
US20050065141A1 (en) 2003-07-31 2005-03-24 Odink Debra A. Carbapenems useful in treating and preventing pulmonary infections, pharmaceutical compositions thereof and modes of administration thereof
EP2085084A1 (en) * 2008-01-29 2009-08-05 LEK Pharmaceuticals D.D. Use of inhibitor of beta-lactamases and its combination with beta-lactam antibiotics
BR112013009531A2 (pt) * 2010-11-11 2016-07-19 Redx Pharma Ltd derivados de fármaco
WO2013088255A1 (en) * 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
CN111700878A (zh) 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015078A1 (en) * 1992-02-04 1993-08-05 Zeneca Limited Carbapenems containing a carboxy substituted phenyl group, processes for their preparation, intermediates and use as antibiotics
US20040176350A1 (en) * 2001-05-21 2004-09-09 Hiroshi Matsui Carbapenem compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TANAKA, S. ET AL., THE JOURNAL OF ANTIBIOTICS, 2011, vol. 64 (3), pages 233 - 242 *

Also Published As

Publication number Publication date
JP2019089829A (ja) 2019-06-13
EP2968274B1 (en) 2019-10-16
US20160039823A1 (en) 2016-02-11
HK1219233A1 (zh) 2017-03-31
AU2014227737A1 (en) 2015-10-08
AU2018203005A1 (en) 2018-05-17
US20210332048A1 (en) 2021-10-28
JP6738918B2 (ja) 2020-08-12
WO2014144285A1 (en) 2014-09-18
EP2968274A4 (en) 2016-08-24
JP2016517435A (ja) 2016-06-16
BR112015023621A8 (pt) 2018-01-23
EP2968274A1 (en) 2016-01-20
CA2906689A1 (en) 2014-09-18
US10392388B2 (en) 2019-08-27
BR112015023621A2 (pt) 2017-07-18
US20200010470A1 (en) 2020-01-09
US11091487B2 (en) 2021-08-17
US9725451B2 (en) 2017-08-08
US20170349590A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
AU2020201184B2 (en) Pharmaceutical nanoparticles showing improved mucosal transport
US20210332048A1 (en) Meropenem derivatives and uses thereof
AU2020203213B2 (en) Pharmaceutical nanoparticles showing improved mucosal transport
CA2900372C (en) Methods of treating topical microbial infections
RU2669800C2 (ru) Способы лечения воспаления, аутоиммунных расстройств и боли
CN108135967A (zh) 用于药物递送的具有渗透增强剂的组合物
US12502433B2 (en) Phosphonate-drug conjugates
CN109937033A (zh) 用于药物递送的具有渗透增强剂的组合物
JP2023041861A (ja) 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤
TWI382839B (zh) 控制釋放之皮質類固醇組成物及其用於耳部失調治療的方法
HK40049934A (en) Pharmaceutical nanoparticles showing improved mucosal transport
HK1216389B (en) Methods of treating topical microbial infections

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: KALA BIO, INC.

Free format text: FORMER NAME(S): KALA PHARMACEUTICALS, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired